NCM
PBE icon

Niemann Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Niemann Capital Management’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-98,154
Closed -$4.09M – 28
2014
Q1 		$4.09M Buy
98,154
+4,047
+4% +$173K 2.78% 13
2013
Q4 		$3.49M Sell
94,107
-6,668
-7% -$239K 2.4% 15
2013
Q3 		$3.53M Buy
+100,775
New +$3.34M 2.54% 14

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TAM
Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
SAM
SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Niemann Capital Management's PBE Position: Q2 2014 in Review

Niemann Capital Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2014, closing a stake of 98,154 shares — an estimated $4.09M sold.

Niemann Capital Management first reported a position in PBE in Q3 2013 and held it in 3 quarters. The position peaked at $4.09M in Q1 2014. 74 funds tracked by Wall St. Rank hold PBE as of Q2 2014.

  • Niemann Capital Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2014 after selling out during the quarter.
  • Niemann Capital Management sold 98,154 Invesco Biotechnology & Genome ETF shares in Q2 2014, an estimated $4.09M.
  • Niemann Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q3 2013 and held it in 3 quarters.
  • Niemann Capital Management's Invesco Biotechnology & Genome ETF position peaked at $4.09M in Q1 2014.
  • 74 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2014.

Based on Niemann Capital Management's 13F filing for Q2 2014, filed 4 Aug 2014.